Organ damage in systemic sclerosis: linking immune activation, vasculopathy, and fibrosis to precision treatment.

INTRODUCTION

Systemic sclerosis (SSc) is a severe autoimmune disease associated with progressive multi-organ damage and increased mortality. Although fibrosis characterizes advanced stages, early disease is marked by immune dysregulation and microvascular injury that precede irreversible organ damage. Failure to recognize these early pathogenic processes contributes to delayed treatment initiation and poorer clinical outcomes.

AREAS COVERED: This review integrates current insights into the mechanisms driving organ damage in SSc, focusing on the interaction between inflammatory, vascular, and tissue-remodeling processes. Organ-specific manifestations affecting the skin, lungs, heart, kidneys, and gastrointestinal tract are discussed. We examine established and emerging biomarkers reflecting inflammatory, vascular, and fibrotic activity, including interferon-related signatures, soluble immune checkpoints, extracellular matrix turnover markers, extracellular vesicle profiles, and dephosphorylated-uncarboxylated matrix Gla protein (dp-ucMGP). In addition, targeted therapeutic strategies aligned with these pathogenic pathways are reviewed.

EXPERT OPINION: SSc is a biologically heterogeneous disease in which the relative contribution of inflammation, vascular dysfunction, and fibrosis varies between patients and across disease stages. Effective management requires early identification of the dominant disease process to guide therapy. Biomarker-informed stratification and mechanism-based treatment approaches may shift care from late-stage organ protection toward earlier disease modification and prevention of irreversible damage.